针刀治疗膝骨关节炎有效性和安全性的多中心随机对照试验

注册号:

Registration number:

ITMCTR2025001408

最近更新日期:

Date of Last Refreshed on:

2025-07-15

注册时间:

Date of Registration:

2025-07-15

注册号状态:

Registration Status:

预注册

Prospective registration

注册题目:

针刀治疗膝骨关节炎有效性和安全性的多中心随机对照试验

Public title:

A randomized controlled trial of the effectiveness and safety of acupotomy therapy for Knee osteoarthritis

注册题目简写:

English Acronym:

研究课题的正式科学名称:

针刀治疗膝骨关节炎有效性和安全性的多中心随机对照试验

Scientific title:

A randomized controlled trial of the effectiveness and safety of acupotomy therapy for Knee osteoarthritis

研究课题的正式科学名称简写:

liudan

Scientific title acronym:

研究课题代号(代码):

Study subject ID:

2023YFC3502701

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

秦懿囡

研究负责人:

张保平

Applicant:

qinyinan

Study leader:

zhangbaoping

申请注册联系人电话:

Applicant telephone:

13752363501

研究负责人电话:

Study leader's telephone:

13619180562

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

qinyinan-0501@163.com

研究负责人电子邮件:

Study leader's E-mail:

837062388@qq.com

申请单位网址(自愿提供):

Study leader's website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website
(voluntary supply):

申请注册联系人通讯地址:

陕西省咸阳市秦都区世纪大道中段12号

研究负责人通讯地址:

陕西省咸阳市西咸新区龙台观路831号

Applicant address:

No. 12 Middle Section Century Avenue Qindu District Xianyang City Shaanxi Province

Study leader's address:

No. 831 Longtaiguan Road Xixian New Area Xianyang City Shaanxi Province

申请注册联系人邮政编码:

Applicant postcode:

712046

研究负责人邮政编码:

Study leader's postcode:

712000

申请人所在单位:

陕西中医药大学

Applicant's institution:

Shaanxi University of Traditional Chinese Medicine

是否获伦理委员会批准:

Approved by ethic committee:

伦理委员会批件文号:

Approved No. of ethic committee:

SZEFYIEC-YJSKYPJ-2025005-3

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件

批准本研究的伦理委员会名称:

陕西中医药大学第二附属医院医学伦理委员会

Name of the ethic committee:

The Medical Ethics Committee of the Second Affiliated Hospital of Shaanxi University of Chinese Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2025/5/9 0:00:00

伦理委员会联系人:

刘丹

Contact Name of the ethic committee:

liudan

伦理委员会联系地址:

陕西省咸阳市西咸新区龙台观路831号

Contact Address of the ethic committee:

No. 831 Longtaiguan Road Xixian New Area Xianyang City Shaanxi Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

029-32223803

伦理委员会联系人邮箱:

Contact email of the ethic committee:

szefyllwyh_1@163.com

研究实施负责(组长)单位:

陕西中医药大学第二附属医院

Primary sponsor:

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine

研究实施负责(组长)单位地址:

陕西省西咸新区新城龙台观路陕西中医药大学第二附属医院

Primary sponsor's address:

The Second Affiliated Hospital of Shaanxi University of Chinese Medicine Longtaiguan Road Xincheng Xixian New Area Shaanxi Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

陕西省

市(区县):

咸阳市

Country:

China

Province:

Shaanxi Province

City:

XianYang

单位(医院):

陕西中医药大学

具体地址:

陕西省咸阳市秦都区世纪大道中段12号

Institution
hospital:

Shaanxi University of Traditional Chinese Medicine

Address:

No. 12, Middle Section, Century Avenue, Qindu District, Xianyang City, Shaanxi Province

国家:

中国

省(直辖市):

陕西省

市(区县):

西咸新区

Country:

Province:

City:

单位(医院):

陕西中医药大学第二附属医院

具体地址:

陕西省西咸新区新城龙台观路陕西中医药大学第二附属医院

Institution
hospital:

Address:

经费或物资来源:

神经节刺激疗法优势病种和诊疗规律的临床多中心评价研究

Source(s) of funding:

Clinical multicenter evaluation research on the advantages of ganglion stimulation therapy in specific diseases and its diagnosis and treatment patterns

研究疾病:

膝骨关节炎

研究疾病代码:

M17.900

Target disease:

knee osteoarthritis

Target disease code:

研究类型:

Study type:

干预性研究

Interventional study

研究设计:

Study design:

随机平行对照

randomized controlled trial(parallel group design)

研究所处阶段:

Study phase:

探索性研究/预试验

Pilot clinical trial

研究目的:

本研究以假针刀作为对照,采用随机、对照、多中心临床随机对照试验,评价针刀治疗KOA的有效性及安全性,优化KOA的临床治疗方案,为针刀治疗KOA有效性提供循证医学证据,为临床治疗提供新的治疗选择。

Objectives of Study:

In this study a randomized controlled multicenter clinical randomized controlled trial was conducted to evaluate the efficacy and safety of needle knife treatment of KOA using a sham needle knife as a control to optimize the clinical treatment protocol of KOA to provide evidence-based medical evidence of the effectiveness of needle knife treatment of KOA and to provide a new therapeutic option for clinical treatment.

药物成份或治疗方案详述:

试验组采用针刀治疗 2 周,每周治疗 1 次,共治疗 2 次。针刀操作点分别选择膝前(膝关节前侧、内、外侧)和膝后进行松解,治疗时按定点、定向、加压分离、刺入 4 步规程操作行针刀治疗。 对照组治疗点的选择与试验组一致,但在操作时只按照四部规程法将针刀刺入皮肤,到相同深度时,不做任何手法操作,停留6~10s以模拟操作时间。

Description for medicine or protocol of treatment in detail:

The experimental group was treated with acupotomy for 2 weeks 1 treatment per week a total of 2 treatments. The acupotomy operation points were selected anterior knee (anterior medial and lateral knee joints) and posterior knee for release and acupotomy therapy was performed according to the 4-step procedure of fixed-point orientation compression separation and puncture. The choice of treatment points in the control group was the same as that of the experimental group but during the operation the needle knife was stabbed into the skin only according to the four-part gauge method to the same depth without any manipulation and stayed for 6~10s to simulate the operation time.

纳入标准:

(1)符合《膝骨关节炎中西医结合诊疗指南》(2023); (2)30岁≤年龄≤65岁,男女不限; (3)临床分期为早、中期且影像学诊断依据(Kellgren-Lawrence分级1、2或3级者); (4)膝关节疼痛程度3≤NRS≤6; (5)最近1个月未使用药物及外治法治疗膝骨关节炎者; (6)从未接受针刀治疗者; (7)愿意参加试验并签署知情同意书。

Inclusion criteria

(1) Compliance with the Guidelines for Integrated Chinese and Western Medicine Diagnosis and Treatment of Knee Osteoarthritis (2023); (2) men or women aged 30–65 years; (3) Clinical staging of early or intermediate stage and imaging diagnosis is based on the Kellgren Lawrence classification 1 2 or 3; (4) Knee joint pain level 3 ≤ NRS ≤ 6; (5) Individuals who have not used medications or external treatments for knee osteoarthritis in the past month; (6) Individuals who have never been received acupotomy treatment; (7) Willingness to participate in the experiment and sign an informed consent form.

排除标准:

(1)合并有严重的疾病(包括心肌梗死或中风、充血性心力衰竭、严重慢性阻塞性肺疾病、肝肾功能衰竭及恶性肿瘤等); (2)有局部皮肤红肿、溃烂、感染、肌肉坏死、深部组织脓肿,合并开放性损伤者; (3)伴有凝血功能异常,有严重的血液系统疾病患者; (4)孕妇及哺乳期妇女; (5)因年老体弱、精神紧张、饥饿、劳累等原因不能耐受针刀治疗者; (6)膝关节畸形者; (7)患有风湿、类风湿性关节炎者; (8)伴有神志疾病不能配合者; (9)同时参加其它临床研究的患者; (10)研究者认为不宜参与本试验的其它情况者。

Exclusion criteria:

1) Combined with serious diseases (including myocardial infarction or stroke congestive heart failure severe slow obstructive pulmonary disease liver and kidney failure and malignant tumors etc.); (2) There are local skin redness ulceration infection muscle necrosis deep tissue abscess combined with openness Sexual injury; (3) Patients with abnormal coagulation function and serious hematologic diseases; (4) Pregnant and lactating women; (5) Those who cannot tolerate acupuncture treatment due to old age frailty mental stress hunger fatigue and other reasons; (6) Knee deformity; (7)Those who suffer from rheumatism and rheumatoid arthritis; (8) Those who are accompanied by mental illness and cannot cooperate; (9) Patients who participate in other clinical studies at the same time; (10) Other conditions that the investigator considers inappropriate to participate in this trial.

研究实施时间:

Study execute time:

From 2025-05-20

To      2026-03-20

征募观察对象时间:

Recruiting time:

From 2025-07-15

To      2025-12-20

干预措施:

Interventions:

组别:

膝骨关节炎针刀干预组

样本量:

60

Group:

Acupotomy group/Sham Acupotomy group

Sample size:

干预措施:

针刀治疗

干预措施代码:

Intervention:

Acupotomy treatment

Intervention code:

组别:

膝骨关节炎假针刀干预组

样本量:

60

Group:

Sham acupotomy intervention group for knee osteoarthritis

Sample size:

干预措施:

假针刀干预

干预措施代码:

Intervention:

Sham acupotomy treatment

Intervention code:

样本总量 Total sample size : 120

研究实施地点:

Countries of recruitment
and research settings:

国家:

中国

省(直辖市):

河南省

市(区县):

洛阳市

Country:

China

Province:

HeNan Province

City:

Luo Yang

单位(医院):

河南省洛阳正骨医院(河南省骨科医院)

单位级别:

三甲

Institution/hospital:

Henan Provincial Orthopedic Hospital (Luoyang Orthopedic Hospital)

Level of the institution:

three-level

国家:

中国

省(直辖市):

陕西省

市(区县):

咸阳市

Country:

China

Province:

Shaanxi Province

City:

Xianyang City

单位(医院):

陕西中医药大学第二附属医院

单位级别:

三甲

Institution/hospital:

The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine

Level of the institution:

three-level

国家:

中国

省(直辖市):

北京

市(区县):

朝阳区

Country:

China

Province:

BeJing

City:

ChaoYang

单位(医院):

中日友好医院

单位级别:

三甲

Institution/hospital:

China--Japan Friendship Hospital

Level of the institution:

three-level

测量指标:

Outcomes:

指标中文名:

生活质量量表12项健康调查简表

指标类型:

次要指标

Outcome:

Medical Outcome Study Short-Form 12 Item Health Survey

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

西安大略和麦克马斯特大学骨关节炎指数量表

指标类型:

主要指标

Outcome:

(Western Ontario and McMaster Universities

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

30s 椅子站立测试

指标类型:

次要指标

Outcome:

30 s chair-stand test

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疗效期待量表

指标类型:

次要指标

Outcome:

Therapeutic Expectancy Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

下蹲时膝关节疼痛数字评价量表

指标类型:

次要指标

Outcome:

numerical rating scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

焦虑自评量表

指标类型:

次要指标

Outcome:

Self-Rating Anxiety Scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

征募研究对象情况:

尚未开始

Not yet recruiting

年龄范围:

最小 30
Min age years
最大 65
Max age years

Recruiting status:

Participant age:

性别:

Gender:

男女均可

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究助理使用SAS 9.4 版(SAS Institute)中的PROC PLAN生成随机化序列,通过中央随机化系统以1:1的比例进行临床研究

Randomization Procedure (please state who generates the random number sequence and by what method):

Research assistants used PROC PLAN in SAS version 9.4 (SAS Institute) to generate randomization sequences to conduct clinical studies at a 1:1 ratio through a centralized randomization system

盲法:

Blinding:

是否共享原始数据:

IPD sharing:

Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2026年12月,期刊发表

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

2026.12,Journal publication

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Electronic Data Capture System, EDC

数据管理委员会:

Data Managemen Committee:

Yes

研究计划书或研究结果报告发表信息
(杂志名称、期、卷、页,时间;或网址):

Publication information of the protocol/research results report
(name of the journal, volume, issue, pages, time; or website):

国际传统医学临床试验注册平台 京ICP备07032215号-5 提示:推荐使用IE8.0以上版本 宽屏显示分辨率下使用系统